Zai Lab logo .png
Zai Lab Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast Cancer in Greater China
05 oct. 2021 07h30 HE | Zai Lab Limited
-- Demonstrated efficacy and safety consistent with global SOPHIA study-- Company expects to file BLA in China in advanced HER2+ breast cancer by approximately year end 2021 SHANGHAI and SAN...
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
16 sept. 2021 02h45 HE | MacroGenics, Inc.
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
07 sept. 2021 16h30 HE | MacroGenics, Inc.
Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumabOS was greater with MARGENZA plus chemotherapy in exploratory subgroups of...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
10 avr. 2021 08h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
25 janv. 2021 07h30 HE | MacroGenics, Inc.
Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb) showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® (trastuzumab), both with...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
16 déc. 2020 16h30 HE | MacroGenics, Inc.
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head...
MacroGenics-Logo-(transparent-background).png
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
30 nov. 2020 16h30 HE | MacroGenics, Inc.
MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expensesEVERSANA may earn revenue share payments over five years subject to predefined capMacroGenics’...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer
09 juil. 2020 18h43 HE | MacroGenics, Inc.
Rockville, MD, July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
05 juin 2020 07h30 HE | MacroGenics, Inc.
Rockville, MD, June 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer
28 mai 2020 07h30 HE | MacroGenics, Inc.
- Advisory committee meeting not required; PDUFA goal date unchanged Rockville, MD, May 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical...